Dr. Reddy's Laboratories moved Tuesday to deepen its commercial foothold in the U.S. oncology generics market as hospital pharmacy networks and specialty distributors began formal formulary review processes for its newly launched generic Bosutinib, the first generic version of Pfizer's Bosulif indicated for chronic myelogenous leukemia (CML). The Hyderabad-based pharmaceutical company, partnering with MSN Laboratories Private Limited, confirmed that initial shipments to specialty oncology distributors had been completed and that payer discussions were progressing ahead of schedule.
Bosutinib, a second-generation BCR-ABL tyrosine kinase inhibitor, has been a standard-of-care option for adult patients with Philadelphia chromosome-positive CML who are resistant or intolerant to prior therapy. With Pfizer's branded Bosulif carrying an annual list price exceeding $180,000, the generic entry from Dr. Reddy's is expected to generate significant cost savings across state Medicaid programmes and private insurers managing CML patient populations.
Major pharmacy benefit managers including CVS Caremark and Express Scripts are expected to complete their expedited formulary tier reviews by the end of the week, with multiple integrated health systems in Texas, Ohio, and New Jersey confirmed to be evaluating substitution protocols. Oncology pharmacists at several National Cancer Institute-designated comprehensive cancer centres said Tuesday they had received product availability notifications and were assessing transition pathways for eligible patients already stabilised on branded Bosulif.
Analysts at HDFC Securities noted that the Bosutinib launch, combined with Dr. Reddy's earlier generic semaglutide approval in Canada, signals an accelerating push by the company to establish dominance in high-value specialty generics. The oncology generics segment is seen as particularly strategic given the relatively small but high-cost patient populations and the limited number of generic competitors expected to enter the Bosutinib market in the near term due to manufacturing complexity.
MSN Laboratories, the Hyderabad-based active pharmaceutical ingredient manufacturer underpinning the partnership, confirmed that its dedicated Bosutinib production line was operating at full capacity and that supply commitments to Dr. Reddy's were secured through at least the end of 2026. Dr. Reddy's management indicated it anticipated generating meaningful revenue contribution from the launch in its fiscal first quarter results, with formal guidance to be provided at the company's upcoming quarterly earnings briefing.